Skip to main content

Table 1 Baseline characteristics of SLE patients, SJS patients, and control subjects

From: The association among leukocyte apoptosis, autoantibodies and disease severity in systemic lupus erythematosus

  SLE patients
(n = 23)
Sjogren's syndrome
(n = 9)
Healthy controls
(n = 20)
Age (y) (mean ± SD) 44.38 ± 10.87 56.56 ± 13.86 48.37 ± 12.01
Male /female 2/21 1/8 6/14
Clinical symptoms Ϯ   
 Constitutional 9 0 ---
 Muco-cutaneous involvement 2 0 ---
 Neurological involvement 14 7 ---
 Musculo-skeletal involvement 15 2 ---
 Cardio-respiratory involvement 2 0 ---
 Renal involvement 3 0 ---
 Hematologic involvement 6 0 ---
Median (IQR) SLEDAI-2 K 11 (6-14)   ---
Mean dosage of medication (mg/day) ξ  
 Prednisolone 21 (mg/day) (n = 15) 3.3 (mg/day) (n = 5) ---
 Hydroxychloroquine 300 (mg/day) (n = 17) 150 (mg/day) (n = 5) ---
 Azathioprine 50 (mg/day) (n = 1) 0 ---
 Mycophenolate 1080 (mg/day) (n = 1) 0 ---
 Cyclophosphamide 500 (mg/month) (n = 2) 0 ---
 Cyclosporine 50 (mg/day) (n = 3) 0 ---
  1. 17 patients who had more than one clinical symptom.
  2. ξ12 patients who took more than one medication.
  3. 4 patients who took more than one medication.
  4. Abbreviations: SLE Systemic lupus erythematosus, SJS Sjogren’s syndrome, IQR Inter-quartile range, SLEDAI-2 K Systemic lupus erythematosus disease activity index 2000.